Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe

Imagem de Miniatura
Arquivos
art_RAFII_Outcomes_of_subsequent_neoplasms_after_umbilical_cord_blood_2023.PDF (380.77 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER
Autores
RAFII, Hanadi
RUGGERI, Annalisa
KENZEY, Chantal
SANZ, Jaime
TOUR, Regis Peffault De la
ESQUIROL, Albert
MICHEL, Gerard
CHEVALLIER, Patrice
RUBIO, Marie-Therese
CORNELISSEN, Jan J.
Citação
BLOOD ADVANCES, v.7, n.10, p.1976-1986, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Subsequent neoplasms (SNs) compromise long-term survivors after hematopoietic cell transplantation. We performed a retrospective analysis of SNs in 10 358 recipients of umbilical cord blood transplantation (UCBT) from 1988 to 2018. SNs developed in 233 patients and 84 were of pediatric age. Indications for UCBT were malignant hematological diseases in 199 patients (85%). Three groups of SNs were observed. Posttransplant lymphoproliferative disorders (PTLD) were reported in 145 patients in a median of 4 months after UCBT. Of these, 9 patients died from relapse, 83 from PTLD, and 24 from transplant-related causes. At last follow-up, 29 were alive; 5-year overall survival (OS) after PTLD diagnosis was 21%. Acute leukemia/myelodysplasia (AL/MDS) was diagnosed in 23 patients in a median of 28 months after UCBT and included 3 donor-cell AL. Four of 23 patients died from relapse of primary disease, 8 from progression of SNs, and 4 from TRM. Seven patients remain alive; the 5-year OS after AL/MDS diagnosis was 36%. Solid tumors (ST) were reported in 65 patients in a median of 54 months after UCBT. Most common tumor sites were lung, thyroid, bone, and soft tissue. A total of 33 patients died (26 owing to ST, 6 to relapse of primary disease, and 1 cause missing). At last follow-up, 32 of 65 patients were alive; the 5-year OS after the diagnosis of ST was 51%. In conclusion, despite their poor outcomes, SNs that occur after UCBT are extremely rare. Identification of risk factors and early detection may help to improve OS.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/54596
Referências
  1. Abbas Fedaey, 2020, World J Transplant, V10, P29, DOI 10.5500/wjt.v10.i2.29
  2. Akhtari M, 2013, CANCER BIOL THER, V14, P1077, DOI 10.4161/cbt.26342
  3. Ando T, 2006, LEUKEMIA, V20, P744, DOI 10.1038/sj.leu.2404121
  4. Armand P, 2007, BIOL BLOOD MARROW TR, V13, P505, DOI 10.1016/j.bbmt.2007.02.005
  5. Atsuta Y, 2014, ANN ONCOL, V25, P435, DOI 10.1093/annonc/mdt558
  6. Baker KS, 2003, J CLIN ONCOL, V21, P1352, DOI 10.1200/JCO.2003.05.108
  7. Ballen KK, 2007, BIOL BLOOD MARROW TR, V13, P82, DOI 10.1016/j.bbmt.2006.08.041
  8. Ballen KK, 2010, BIOL BLOOD MARROW TR, V16, P1025, DOI 10.1016/j.bbmt.2010.02.014
  9. Bhatia S, 2011, EXPERT REV HEMATOL, V4, P437, DOI [10.1586/ehm.11.39, 10.1586/EHM.11.39]
  10. Blaes AH, 2010, BIOL BLOOD MARROW TR, V16, P287, DOI 10.1016/j.bbmt.2009.10.008
  11. Brunstein CG, 2002, BONE MARROW TRANSPL, V29, P999, DOI 10.1038/sj.bmt.1703577
  12. Brunstein CG, 2007, BLOOD, V110, P3064, DOI 10.1182/blood-2007-04-067215
  13. Brunstein CG, 2006, BLOOD, V108, P2874, DOI 10.1182/blood-2006-03-011791
  14. Curtis RE, 1999, BLOOD, V94, P2208
  15. Cutting RJ, 2008, BONE MARROW TRANSPL, V42, P631, DOI 10.1038/bmt.2008.224
  16. Danylesko I, 2018, CURR TREAT OPTION ON, V19, DOI 10.1007/s11864-018-0528-y
  17. Ditschkowski M, 2009, BONE MARROW TRANSPL, V44, P265, DOI 10.1038/bmt.2009.8
  18. Dumas PY, 2013, BONE MARROW TRANSPL, V48, P253, DOI 10.1038/bmt.2012.117
  19. Ehrhardt MJ, 2016, BONE MARROW TRANSPL, V51, P83, DOI 10.1038/bmt.2015.203
  20. Engel N, 2019, LEUKEMIA, V33, P508, DOI 10.1038/s41375-018-0218-6
  21. Bonong PRE, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030288
  22. Flynn CM, 2007, BLOOD, V109, P2688, DOI 10.1182/blood-2006-07-021980
  23. Fraser CJ, 2005, BLOOD, V106, P4377, DOI 10.1182/blood-2005-06-2551
  24. Gallagher G, 2007, CANCER, V109, P84, DOI 10.1002/cncr.22375
  25. Gilliland DG, 2002, BIOL BLOOD MARROW TR, V8, P9, DOI 10.1053/bbmt.2002.v8.pm11846355
  26. Gong JZ, 2006, AM J SURG PATHOL, V30, P328
  27. Greaves MF, 2006, LEUKEMIA, V20, P1633, DOI 10.1038/sj.leu.2404293
  28. Hertenstein B, 2005, HAEMATOLOGICA, V90, P969
  29. Hou HA, 2009, BONE MARROW TRANSPL, V43, P315, DOI 10.1038/bmt.2008.325
  30. Icheva V, 2013, J CLIN ONCOL, V31, P39, DOI 10.1200/JCO.2011.39.8495
  31. Inamoto Y, 2015, BONE MARROW TRANSPL, V50, P1013, DOI 10.1038/bmt.2015.63
  32. Knight JS, 2009, J CLIN ONCOL, V27, P3354, DOI 10.1200/JCO.2008.20.0857
  33. Konuma T, 2009, BONE MARROW TRANSPL, V43, P429, DOI 10.1038/bmt.2008.344
  34. Landgren O, 2009, BLOOD, V113, P4992, DOI 10.1182/blood-2008-09-178046
  35. Lowe T, 2007, BIOL BLOOD MARROW TR, V13, P1121, DOI 10.1016/j.bbmt.2007.07.002
  36. Majhail NS, 2011, BRIT J HAEMATOL, V154, P301, DOI 10.1111/j.1365-2141.2011.08756.x
  37. Majhail NS, 2011, BLOOD, V117, P316, DOI 10.1182/blood-2010-07-294629
  38. Majhail Navneet S, 2008, Hematology Am Soc Hematol Educ Program, P142, DOI 10.1182/asheducation-2008.1.142
  39. Martin PJ, 2006, BIOL BLOOD MARROW TR, V12, P491, DOI 10.1016/j.bbmt.2006.03.004
  40. Matsunaga T, 2012, INT J HEMATOL, V96, P342, DOI 10.1007/s12185-012-1146-2
  41. Ocheni S, 2008, BONE MARROW TRANSPL, V42, P181, DOI 10.1038/bmt.2008.150
  42. Peric Z, 2012, BONE MARROW TRANSPL, V47, P251, DOI 10.1038/bmt.2011.64
  43. PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825
  44. Rheingold S.R., 2003, HOLLAND FREI CANC ME, V6th ed.
  45. Ricciardelli I, 2014, BLOOD, V124, P2514, DOI 10.1182/blood-2014-01-553362
  46. Ringden O, 2014, BIOL BLOOD MARROW TR, V20, P1777, DOI 10.1016/j.bbmt.2014.07.009
  47. Rizzo JD, 2009, BLOOD, V113, P1175, DOI 10.1182/blood-2008-05-158782
  48. Rowlings PA, 1999, J CLIN ONCOL, V17, P3122, DOI 10.1200/JCO.1999.17.10.3122
  49. Sala-Torra O, 2006, BIOL BLOOD MARROW TR, V12, P511, DOI 10.1016/j.bbmt.2006.01.006
  50. Sanz J, 2014, BONE MARROW TRANSPL, V49, P397, DOI 10.1038/bmt.2013.190
  51. Shimada K, 2005, BONE MARROW TRANSPL, V36, P115, DOI 10.1038/sj.bmt.1705020
  52. Shimoni A, 2013, LEUKEMIA, V27, P829, DOI 10.1038/leu.2012.299
  53. Shiozaki H, 2014, BONE MARROW TRANSPL, V49, P102, DOI 10.1038/bmt.2013.127
  54. Socie G, 2007, BLOOD, V109, P2794, DOI 10.1182/blood-2006-07-034272
  55. Spyridonidis A, 2020, BONE MARROW TRANSPL, V55, P1114, DOI 10.1038/s41409-020-0803-y
  56. Styczynski J, 2016, HAEMATOLOGICA, V101, P803, DOI 10.3324/haematol.2016.144428
  57. Styczynski J, 2013, CLIN INFECT DIS, V57, P794, DOI 10.1093/cid/cit391
  58. Syrjala KL, 2012, J CLIN ONCOL, V30, P3746, DOI 10.1200/JCO.2012.42.3038
  59. Takahashi S, 2007, BLOOD, V109, P1322, DOI 10.1182/blood-2006-04-020172
  60. Tichelli A, 2019, JAMA ONCOL, V5, P229, DOI 10.1001/jamaoncol.2018.4934
  61. Tichelli A, 2012, CURR PROBL DERMATOL, V43, P132, DOI 10.1159/000335271
  62. Uhlin M, 2014, HAEMATOLOGICA, V99, P346, DOI 10.3324/haematol.2013.087338
  63. Wiseman DH, 2011, BIOL BLOOD MARROW TR, V17, P771, DOI 10.1016/j.bbmt.2010.10.010
  64. Yamasaki S, 2017, BONE MARROW TRANSPL, V52, P969, DOI 10.1038/bmt.2017.52

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - ODS/03